Frank McCormick's Stock Sale Plan at BridgeBio Pharma

Frank McCormick, a director at BridgeBio Pharma, has filed a Form 144 to report his intention to sell shares under a 10b5-1 plan. The plan was adopted on August 28, 2024, and the shares to be sold were acquired on October 1, 2021, as part of a stock bonus. McCormick plans to sell 1641 shares of common stock, with an aggregate market value of $106,665, on or around October 27, 2025. Additionally, McCormick has reported a recent sale of 74,000 shares on September 5, 2025, which generated gross proceeds of $3,932,056. The shares are held on the Nasdaq exchange, and the sale will be facilitated by Merrill Lynch. This filing is a routine disclosure under SEC regulations and does not indicate any significant change in the company's operations or financial health.